CrossTalk proposal: The late sodium current is an important player in the development of diastolic heart failure (heart failure with a preserved ejection fraction)

Journal of Physiology

Volumn 592, Issue 3, 2014, Pages 411-414

  Pourrier, Marc ^a   Williams, Sarah ^a   Mcafee, Donald ^a   Belardinelli, Luiz ^b   Fedida, David ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Gilead Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANOLAZINE; SODIUM CHANNEL;

ANGINA PECTORIS; ARTICLE; CALCIUM CELL LEVEL; CORONARY ARTERY DISEASE; DIASTOLIC DYSFUNCTION; DIASTOLIC HEART FAILURE; EXPERIMENTAL HEART FAILURE; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; ISCHEMIC HEART DISEASE; LONG QT SYNDROME 3; LUNG ARTERY PRESSURE; NONHUMAN; PRIORITY JOURNAL; SODIUM CURRENT; SODIUM TRANSPORT;

ANIMALS; DIASTOLE; HEART FAILURE; HUMANS; SODIUM; SODIUM CHANNELS; STROKE VOLUME;

EID: 84893348933     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2013.262261     Document Type: Article

References (32)

1. Aistrup GL, Gupta DK, Kelly JE, O'Toole MJ, Nahhas AF, Chirayil N, Misener S, Beussink L, Singh N, Ng J, Reddy M, Mongkolrattanothai T, El Bizri N, Rajamani S, Shryock JC, Belardinelli L, Shah SJ & Wasserstrom JA (2013). Inhibition of the late sodium current slows t-tubule disruption during the progression of hypertensive heart disease in the rat. Am J Physiol Heart Circ Physiol 305, H1068-H1079.
2. Belardinelli L, Liu G, Smith-Maxwell C, Wang WQ, El Bizri N, Hirakawa R, Karpinski S, Li CH, Hu L, Li XJ, Crumb W, Wu L, Koltun D, Zablocki J, Yao L, Dhalla AK, Rajamani S & Shryock JC (2013). A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. J Pharmacol Exp Ther 344, 23-32.
3. Borlaug BA & Paulus WJ (2011). Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 32, 670-679.
4. Coppini R, Ferrantini C, Yao L, Fan P, Del Lungo M, Stillitano F, Sartiani L, Tosi B, Suffredini S, Tesi C, Yacoub M, Olivotto I, Belardinelli L, Poggesi C, Cerbai E & Mugelli A (2013). Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation 127, 575-584.
5. Derangeon M, Montnach J, Baró I & Charpentier F (2012). Mouse models of SCN5A-related cardiac arrhythmias. Front Physiol 3, 210.
6. Doi R, Masuyama T, Yamamoto K, Doi Y, Mano T, Sakata Y, Ono K, Kuzuya T, Hirota S, Koyama T, Miwa T & Hori M (2000). Development of different phenotypes of hypertensive heart failure: systolic versus diastolic failure in Dahl salt- sensitive rats. J Hypertens. 18, 111-120.
7. Figueredo VM, Pressman GS, Romero-Corral A, Murdock E, Holderbach P & Morris DL (2011). Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina. J Cardiovasc Pharmacol Ther 16, 168-172.
8. Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ & Clanachan AS (2006). Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol 41, 1031-1038.
9. Hayashida W, van Eyll C, Rousseau MF & Pouleur H (1994). Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther 8, 741-747.
10. Hummel YM, Wilde AA, Voors AA, Bugatti S, Hillege HL & Van den Berg MP (2013). Ventricular dysfunction in a family with long QT syndrome type 3. Europace 15, 1516-1521.
11. LeGrice IJ, Pope AJ, Sands GB, Whalley G, Doughty RN & Smaill BH (2012). Progression of myocardial remodeling and mechanical dysfunction in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 303, H1353-H1365.
12. Maier LS (2012). New treatment options for late Na current, arrhythmias, and diastolic dysfunction. Curr Heart Fail Rep 9, 183-191.
13. Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, Lang C, Wachter R, Edelmann F, Hasenfuss G & Jacobshagen C (2013). RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: The RALI-DHF Proof-of-Concept Study. J Am Coll Cardiol 1, 115-122.
14. + current in human ventricle: implications for sodium loading and homeostasis. J Cardiovasc Electrophysiol 17 (Suppl. 1), S15-S20.
15. Maltsev VA, Silverman N, Sabbah HN & Undrovinas AI (2007). Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability. Eur J Heart Fail 9, 219-227.
16. Maltsev VA & Undrovinas A (2008). Late sodium current in failing heart: friend or foe? Prog Biophys Mol Biol 96, 421-451.
17. Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S & Robinson JL (2008). Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol 19, 1289-1293.
18. Noble D & Noble PJ (2006). Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. Heart 92 (Suppl. 4), iv1-iv5.
19. 2+ load in human heart failure. Basic Res Cardiol 97 (Suppl. 1), I63-I71.
20. 2-induced increase in late sodium current in ventricular myocytes. PLoS One 7, e51358.
21. Rastogi S, Sharov VG, Mishra S, Gupta RC, Blackburn B, Belardinelli L, Stanley WC & Sabbah HN (2008). Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol 295, H2149-H2155.
22. Sabbah HN, Chandler MP, Mishima T, Suzuki G, Chaudhry P, Nass O, Biesiadecki BJ, Blackburn B, Wolff A & Stanley WC (2002). Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 8, 416-422.
23. Selby DE, Palmer BM, LeWinter MM & Meyer M (2011). Tachycardia-induced diastolic dysfunction and resting tone in myocardium from patients with a normal ejection fraction. J Am Coll Cardiol 58, 147-154.
24. Na in the cardiomyocyte. Cardiovasc Res 99, 600-611.
25. Sossalla S, Wagner S, Rasenack EC, Ruff H, Weber SL, Schondube FA, Tirilomis T, Tenderich G, Hasenfuss G, Belardinelli L & Maier LS (2008). Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts - role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 45, 32-43.
26. Toischer K, Hartmann N, Wagner S, Fischer TH, Herting J, Danner BC, Sag CM, Hund TJ, Mohler PJ, Belardinelli L, Hasenfuss G, Maier LS & Sossalla S (2013). Role of late sodium current as a potential arrhythmogenic mechanism in the progression of pressure-induced heart disease. J Mol Cell Cardiol 61, 111-122.
27. 2+ accumulation in chronic heart failure. J Physiol Sci 60, 245-257.
28. Valdivia CR, Chu WW, Pu J, Foell JD, Haworth RA, Wolff MR, Kamp TJ & Makielski JC (2005). Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. J Mol Cell Cardiol 38, 475-483.
29. Venkataraman R, Chen J, Garcia EV, Belardinelli L, Hage FG, Heo J & Iskandrian AE (2012). Effect of ranolazine on left ventricular dyssynchrony in patients with coronary artery disease. Am J Cardiol 110, 1440-1445.
30. Xi Y, Wu G, Yang L, Han K, Du Y, Wang T, Lei X, Bai X & Ma A (2009). Increased late sodium currents are related to transcription of neuronal isoforms in a pressure-overload model. Eur J Heart Fail 11, 749-757.
31. Yang T, Atack TC, Stroud DM, Zhang W, Hall L & Roden DM (2012). Blocking Scn10a channels in heart reduces late sodium current and is antiarrhythmic. Circ Res 111, 322-332.
32. Zaza A, Belardinelli L & Shryock JC (2008). Pathophysiology and pharmacology of the cardiac "late sodium current." Pharmacol Ther 119, 326-339.